MA34002B1 - Thérapie antivirale - Google Patents

Thérapie antivirale

Info

Publication number
MA34002B1
MA34002B1 MA35145A MA35145A MA34002B1 MA 34002 B1 MA34002 B1 MA 34002B1 MA 35145 A MA35145 A MA 35145A MA 35145 A MA35145 A MA 35145A MA 34002 B1 MA34002 B1 MA 34002B1
Authority
MA
Morocco
Prior art keywords
antiviral therapy
treatment
hiv
aids
combinations
Prior art date
Application number
MA35145A
Other languages
Arabic (ar)
English (en)
Inventor
Mark Richard Underwood
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34002(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of MA34002B1 publication Critical patent/MA34002B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La présente invention concerne des combinaisons de composés comprenant des inhibiteurs de l'intégrase du vih et d'autres agents thérapeutiques. Lesdites combinaisons peuvent être utilisées dans le cadre de l'inhibition de la réplication du vih, de la prévention et/ou du traitement de l'infection par le vih et du traitement du sida et/ou du syndrome pré-sida.
MA35145A 2010-01-27 2011-01-24 Thérapie antivirale MA34002B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29858910P 2010-01-27 2010-01-27
PCT/US2011/022219 WO2011094150A1 (fr) 2010-01-27 2011-01-24 Thérapie antivirale

Publications (1)

Publication Number Publication Date
MA34002B1 true MA34002B1 (fr) 2013-02-01

Family

ID=44319704

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35145A MA34002B1 (fr) 2010-01-27 2011-01-24 Thérapie antivirale

Country Status (45)

Country Link
US (12) US20120295898A1 (fr)
EP (6) EP2932970B1 (fr)
JP (8) JP2013518107A (fr)
KR (4) KR101830715B1 (fr)
CN (2) CN102791129B (fr)
AP (1) AP3551A (fr)
AU (1) AU2011209788C1 (fr)
BR (1) BR112012018670A2 (fr)
CA (4) CA3060290C (fr)
CL (1) CL2012002080A1 (fr)
CO (1) CO6602152A2 (fr)
CR (1) CR20120423A (fr)
CY (4) CY1116509T1 (fr)
DK (4) DK3494972T3 (fr)
DO (2) DOP2012000205A (fr)
EA (4) EA202190473A3 (fr)
EC (1) ECSP12012106A (fr)
ES (4) ES2688925T3 (fr)
FI (2) FI3494972T3 (fr)
FR (1) FR18C1043I2 (fr)
HK (3) HK1250335A1 (fr)
HR (4) HRP20240168T1 (fr)
HU (4) HUE040554T2 (fr)
IL (5) IL221007A (fr)
LT (4) LT2932970T (fr)
LU (1) LUC00090I2 (fr)
MA (1) MA34002B1 (fr)
ME (2) ME02182B (fr)
MX (4) MX2012008774A (fr)
MY (1) MY188334A (fr)
NO (2) NO2932970T3 (fr)
NZ (4) NZ627826A (fr)
PE (2) PE20121524A1 (fr)
PH (2) PH12016500195A1 (fr)
PL (4) PL2932970T3 (fr)
PT (4) PT3494972T (fr)
RS (4) RS65183B1 (fr)
SG (3) SG10201509476RA (fr)
SI (4) SI2932970T1 (fr)
SM (1) SMT201500177B (fr)
TN (1) TN2012000376A1 (fr)
TR (1) TR201807704T4 (fr)
UA (1) UA105556C2 (fr)
WO (1) WO2011094150A1 (fr)
ZA (1) ZA201205586B (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2688925T3 (es) 2010-01-27 2018-11-07 Viiv Healthcare Company Tratamiento antiviral
CN104884063A (zh) 2012-10-23 2015-09-02 西普拉有限公司 抗逆转录病毒药物组合物
KR102527797B1 (ko) 2012-12-21 2023-05-03 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
EP2956123A1 (fr) 2013-02-18 2015-12-23 ratiopharm GmbH Forme galénique pharmaceutique solide de dolutegravir
EP2767272A1 (fr) * 2013-02-18 2014-08-20 Ratiopharm GmbH Forme posologique pharmaceutique solide de dolutegravir
CA2916993C (fr) 2013-07-12 2019-01-15 Gilead Sciences, Inc. Composes polycycliques-carbomoylpyridone et leur utilisation pharmaceutique
NO2865735T3 (fr) 2013-07-12 2018-07-21
EA030695B1 (ru) 2013-09-27 2018-09-28 Мерк Шарп И Доум Корп. Замещенные производные хинолизина, которые можно использовать как ингибиторы интегразы вич
WO2015140569A1 (fr) 2014-03-20 2015-09-24 Cipla Limited Composition pharmaceutique
CA2950911C (fr) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Utilisation d'un inhibiteur des antagonistes de la proteine d'apoptose (iap) dans une therapie contre le vih
TWI744723B (zh) 2014-06-20 2021-11-01 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
NO2717902T3 (fr) 2014-06-20 2018-06-23
EP3177629B1 (fr) 2014-07-29 2020-01-29 LEK Pharmaceuticals d.d. Nouveaux hydrates de sodium de dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
AU2016244035B2 (en) 2015-04-02 2018-11-01 Gilead Sciences, Inc. Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017029225A1 (fr) * 2015-08-14 2017-02-23 Sandoz Ag Composition pharmaceutique solide d'abacavir, de lamivudine et d'efavirenz
WO2017205585A1 (fr) * 2016-05-27 2017-11-30 Viiv Healthcare Company Combinaisons, utilisations et traitements correspondants
WO2018028841A1 (fr) * 2016-08-12 2018-02-15 Sandoz Ag Composé pharmaceutique solide d'abacavir, de lamivudine et d'éfavirenz.
WO2018042332A1 (fr) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinaisons, utilisations et traitements correspondants
US20200138845A1 (en) * 2017-07-18 2020-05-07 Viiv Healthcare Company Combination Drug Therapy
KR20200031658A (ko) 2017-07-21 2020-03-24 비이브 헬쓰케어 컴퍼니 Hib 감염 및 aids를 치료하기 위한 요법
EP3654981A4 (fr) * 2017-07-21 2021-04-21 VIIV Healthcare Company Régimes et préparations pour le traitement des infections à vih et du sida
KR20200070246A (ko) * 2017-10-13 2020-06-17 비이브 헬쓰케어 컴퍼니 이중층 제약 정제 제제
EP4122537A1 (fr) 2019-03-22 2023-01-25 Gilead Sciences, Inc. Composés tricycliques pontés de carbamoylpyridone et leur utilisation pharmaceutique
CN114901363A (zh) * 2020-01-09 2022-08-12 华盛顿大学 长效治疗剂组合物及其方法
US11697652B2 (en) 2020-02-24 2023-07-11 Gilead Sciences, Inc. Tetracyclic compounds and uses thereof
WO2022159387A1 (fr) 2021-01-19 2022-07-28 Gilead Sciences, Inc. Composés de pyridotriazine substitués et leurs utilisations
WO2023164293A1 (fr) * 2022-02-28 2023-08-31 Jericho Sciences, Llc Méthodes d'infections virales

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047407A (en) 1989-02-08 1991-09-10 Iaf Biochem International, Inc. 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en) 1989-02-08 2006-10-10 Glaxo Wellcome Inc. Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
GB9009861D0 (en) 1990-05-02 1990-06-27 Glaxo Group Ltd Chemical compounds
ZA923640B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
US5519021A (en) 1992-08-07 1996-05-21 Merck & Co., Inc. Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en) 1992-08-07 1997-11-20 Merck & Co Inc Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en) 1994-02-04 1994-03-30 Wellcome Found Chloropyrimidine intermediates
IL113432A (en) 1994-04-23 2000-11-21 Glaxo Group Ltd Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk) 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
MY115461A (en) 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5849911A (en) 1996-04-22 1998-12-15 Novartis Finance Corporation Antivirally active heterocyclic azahexane derivatives
HUP9903249A3 (en) * 1996-06-25 2001-04-28 Glaxo Group Ltd Combinations comprising vx478, zidovudine, ftc and/or 3tc for use in the treatment of hiv
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en) 1997-02-05 1999-10-12 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en) 1997-05-17 1997-07-09 Glaxo Group Ltd A novel salt
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
GB9717928D0 (en) 1997-08-22 1997-10-29 Glaxo Group Ltd Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en) 1997-10-14 1997-12-10 Glaxo Group Ltd Process for the synthesis of chloropurine intermediates
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6087383A (en) 1998-01-20 2000-07-11 Bristol-Myers Squibb Company Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en) 1998-03-20 1998-05-13 Glaxo Group Ltd Process for the sythesis of hiv protease inhibitors
EP1063888A1 (fr) 1998-03-27 2001-01-03 The Regents of the University of California Nouveaux inhibiteurs de vih integrase et traitement du vih fonde sur des combinaisons de medicaments contenant des inhibiteurs d'integrase
UA72207C2 (uk) 1998-04-07 2005-02-15 Брістол- Майєрс Сквібб Фарма Компані Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) * 1998-04-29 1998-07-01 Glaxo Group Ltd Pharmaceutical compositions
GB9815567D0 (en) 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
ES2286097T7 (es) 2000-01-31 2009-11-05 Cook Biotech, Inc Valvulas de endoprotesis.
DE60219292T2 (de) 2001-04-10 2008-04-10 Pfizer Inc. Pyrazolderivate zur behandlung von hiv
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
AR040242A1 (es) * 2002-06-04 2005-03-23 Glaxo Group Ltd Composiciones farmaceuticas
PL373758A1 (en) * 2002-06-27 2005-09-05 Medivir Ab Synergistic interaction of abacavir and alovudine
US20040224917A1 (en) * 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
TW200510425A (en) 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
BRPI0507628A (pt) * 2004-02-11 2007-07-03 Smithkline Beecham Corp composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto
ES2315922T3 (es) * 2004-04-14 2009-04-01 Gilead Sciences, Inc. Analogos de fosfonato de compuestos inhibidores de la integrasa del vih.
EP2229945A1 (fr) * 2004-05-21 2010-09-22 Japan Tobacco, Inc. Associations comprenant un derivee de 4-isoquinolone et des agents anti-HIV
US7176196B2 (en) 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
CA2576659A1 (fr) 2004-08-23 2006-03-02 Teva Pharmaceutical Industries Ltd. Sodium d'ibandronate solide cristallin et ses procedes de preparation
PL1632232T6 (pl) 2004-09-02 2022-06-27 Janssen Pharmaceutica Nv Sól 4-[[4-[[4-(2-cyjanoetenylo)-2,6-dimetylofenylo]amino]-2-pirymidynylo]amino]benzonitrylu
RS50981B (sr) 2004-09-17 2010-10-31 Idenix Pharmaceuticals Inc. Fosfoindoli kao hiv inhibitori
EP1853604A4 (fr) 2005-03-04 2010-02-24 Smithkline Beecham Corp Composes chimiques
WO2006116764A1 (fr) * 2005-04-28 2006-11-02 Smithkline Beecham Corporation Derive polycyclique de la carbamoylpyridone a activite inhibitrice sur l'integrase du vih
UA96568C2 (en) * 2005-04-28 2011-11-25 Глаксосмиткляйн Ллк Polycyclic carbamoyl pyridone derivative as hiv-integrase inhibitor
EP2308490A1 (fr) * 2005-12-30 2011-04-13 Gilead Sciences, Inc. Procedes pour l'amelioration de la pharmacocinetique d'inhibiteurs de l'integrase vih
UA108605C2 (uk) * 2005-12-30 2015-05-25 Спосіб покращення фармакокінетики інгібіторів інтегрази віл
TWI458483B (zh) * 2006-01-20 2014-11-01 Tibotec Pharm Ltd Ｈｉｖ感染之長期治療
US20080039428A1 (en) 2006-06-29 2008-02-14 Panacos Pharmaceuticals, Inc. Antiretroviral combination therapy
CA2657936C (fr) 2006-07-21 2017-01-10 Gilead Sciences, Inc. Inhibiteurs de protease antiviraux
US7960428B2 (en) 2006-09-29 2011-06-14 Idenix Pharmaceuticals, Inc. Enantiomerically pure phosphoindoles as HIV inhibitors
ES2603617T3 (es) 2007-02-23 2017-02-28 Gilead Sciences, Inc. Moduladores de propiedades farmacocinéticas de la terapéutica
TW200835693A (en) 2007-02-23 2008-09-01 Auspex Pharmaceuticals Inc Preparation and utility of non-nucleoside reverse transcriptase inhibitors
KR20100041798A (ko) 2007-06-29 2010-04-22 한국화학연구원 신규 ｈｉｖ 역전사효소 억제제
CA2692460A1 (fr) 2007-06-29 2009-01-08 Korea Research Institute Of Chemical Technology Inhibiteurs de la transcriptase inverse du vih
JP5393665B2 (ja) 2007-07-06 2014-01-22 ギリアード サイエンシーズ， インコーポレイテッド 治療剤の薬物動態特性の調整剤
DK2175857T3 (da) * 2007-07-12 2013-12-02 Janssen R & D Ireland Krystallinsk form af (e) 4-[[4-[[4-(2-cyanoethenyl)-2.6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitril
WO2009058923A1 (fr) 2007-10-31 2009-05-07 Smithkline Beecham Corporation Antagonistes de ccr5 en tant qu'agents thérapeutiques
JP2011502998A (ja) 2007-11-01 2011-01-27 ザ ユーエイビー リサーチ ファウンデイション ウイルス感染の治療および予防
US8108055B2 (en) 2007-12-28 2012-01-31 Larry Wong Method, system and apparatus for controlling an electrical device
MX2010007375A (es) * 2008-01-03 2010-09-30 Virochem Pharma Inc Nuevos derivados de lupano.
EP2240504A1 (fr) 2008-01-03 2010-10-20 Virochem Pharma Inc. Préparation de nouveaux dérivés de c-21-céto lupane et leur utilisation
EP2231628B1 (fr) 2008-01-04 2015-10-28 Gilead Sciences, Inc. Inhibiteurs du cytrochrome p450
WO2009100532A1 (fr) 2008-02-14 2009-08-20 Virochem Pharma Inc. Nouveaux dérivés de 17ss-lupane
WO2009148600A2 (fr) * 2008-06-06 2009-12-10 Concert Pharmaceuticals, Inc. Composés à base de lysine deutérée
PT2320908E (pt) * 2008-07-25 2014-03-06 Shionogi & Co Pró-fármacos de dolutegravir
MX2011006241A (es) * 2008-12-11 2011-06-28 Shionogi & Co Sintesis de inhibidores de integrasa de vih de carbamoil-piridona e intermediarios.
ES2964383T3 (es) 2008-12-11 2024-04-05 Viiv Healthcare Co Procesos e intermedios para inhibidores de la integrasa del VIH de carbamoilpiridona
ES2688925T3 (es) 2010-01-27 2018-11-07 Viiv Healthcare Company Tratamiento antiviral
GB201006038D0 (en) 2010-04-12 2010-05-26 Unilever Plc Improvements relating to antiviral compositions
CN103402516B (zh) 2010-06-17 2018-01-30 富津世生物技术有限公司 用作抗病毒药物的化合物、组合物及使用方法

Also Published As

Publication number Publication date
JP2019167371A (ja) 2019-10-03
CA3003988C (fr) 2020-01-07
EP3351249A1 (fr) 2018-07-25
CN105311033B (zh) 2019-05-07
WO2011094150A1 (fr) 2011-08-04
HK1179522A1 (en) 2013-10-04
DK3494972T3 (da) 2024-01-29
KR101883750B1 (ko) 2018-07-31
EA202190473A3 (ru) 2021-12-31
CY1120457T1 (el) 2019-07-10
CA2787691C (fr) 2018-07-17
JP2022071126A (ja) 2022-05-13
NZ627824A (en) 2016-02-26
NZ601319A (en) 2014-08-29
IL281959A (en) 2021-05-31
CY1116509T1 (el) 2017-03-15
PT2932970T (pt) 2018-06-08
EP3494972A1 (fr) 2019-06-12
AU2011209788A1 (en) 2012-08-16
ME03058B (fr) 2019-01-20
US20170119777A1 (en) 2017-05-04
US20180098992A1 (en) 2018-04-12
HUE037812T2 (hu) 2018-09-28
FR18C1043I2 (fr) 2019-10-11
TN2012000376A1 (en) 2014-01-30
RS54123B1 (en) 2015-12-31
EA025176B1 (ru) 2016-11-30
US20170079982A1 (en) 2017-03-23
CO6602152A2 (es) 2013-01-18
US20170281636A1 (en) 2017-10-05
ES2969969T3 (es) 2024-05-23
ES2688925T3 (es) 2018-11-07
DK3127542T3 (en) 2018-11-12
MX367937B (es) 2019-09-12
IL267658B (en) 2021-04-29
MX356891B (es) 2018-06-19
DK2531027T3 (en) 2015-07-20
HUE026849T2 (en) 2016-08-29
HRP20180855T1 (hr) 2018-06-29
PH12018502489A1 (en) 2020-06-15
EP4316599A2 (fr) 2024-02-07
NZ627827A (en) 2016-02-26
KR101964923B1 (ko) 2019-04-02
HK1250335A1 (zh) 2018-12-14
NZ627826A (en) 2016-01-29
LTPA2018013I1 (lt) 2018-11-12
EA202190473A2 (ru) 2021-06-30
AU2011209788C1 (en) 2014-08-28
EA201690872A2 (ru) 2016-08-31
SMT201500177B (it) 2015-09-07
SI2531027T1 (sl) 2015-08-31
PT2531027E (pt) 2015-09-16
CA3060290C (fr) 2022-07-12
CN102791129B (zh) 2015-09-30
RS57323B1 (sr) 2018-08-31
SG182614A1 (en) 2012-08-30
JP2023085431A (ja) 2023-06-20
KR20180078358A (ko) 2018-07-09
US20160199379A1 (en) 2016-07-14
US20160339033A1 (en) 2016-11-24
IL245182A0 (en) 2016-06-30
SG10201509476RA (en) 2015-12-30
CN105311033A (zh) 2016-02-10
KR101830715B1 (ko) 2018-04-04
HRP20181531T1 (hr) 2018-11-16
US20120295898A1 (en) 2012-11-22
UA105556C2 (uk) 2014-05-26
CA2787691A1 (fr) 2011-08-04
EA032868B1 (ru) 2019-07-31
US10426780B2 (en) 2019-10-01
SI3494972T1 (sl) 2024-03-29
PH12016500195B1 (en) 2016-12-05
CY2018029I1 (el) 2019-07-10
PE20121524A1 (es) 2012-12-03
ES2670811T3 (es) 2018-06-01
EP2531027B1 (fr) 2015-05-06
HUS1800042I1 (hu) 2018-11-28
JP2013518107A (ja) 2013-05-20
IL245182B (en) 2018-04-30
CY2018029I2 (el) 2019-07-10
HRP20240168T1 (hr) 2024-04-26
IL221007A (en) 2016-06-30
LUC00090I2 (fr) 2019-01-08
JP2017008087A (ja) 2017-01-12
DK2932970T3 (en) 2018-05-28
PL3127542T3 (pl) 2019-03-29
CA3003988A1 (fr) 2011-08-04
IL257267A (en) 2018-03-29
ME02182B (me) 2015-10-20
KR20120128640A (ko) 2012-11-27
US20180200254A1 (en) 2018-07-19
US11234985B2 (en) 2022-02-01
DOP2021000147A (es) 2022-01-16
PT3494972T (pt) 2024-02-12
EP2531027A4 (fr) 2013-07-03
US20170216284A1 (en) 2017-08-03
HK1209629A1 (en) 2016-04-08
HUE040554T2 (hu) 2019-03-28
LT2932970T (lt) 2018-06-25
IL257267B (en) 2019-08-29
KR20170078868A (ko) 2017-07-07
KR20160111536A (ko) 2016-09-26
RS57728B1 (sr) 2018-12-31
IL281959B (en) 2021-12-01
PE20160180A1 (es) 2016-05-04
ZA201205586B (en) 2014-01-29
ECSP12012106A (es) 2013-05-31
EA201690872A3 (ru) 2016-12-30
CA2967453A1 (fr) 2011-08-04
DOP2012000205A (es) 2012-10-15
SI2932970T1 (en) 2018-07-31
TR201807704T4 (tr) 2018-06-21
LTC2932970I2 (lt) 2022-04-25
EA201892277A1 (ru) 2019-03-29
EP4316599A3 (fr) 2024-04-10
EP2932970A1 (fr) 2015-10-21
FIC20240016I1 (fi) 2024-05-31
PL2531027T3 (pl) 2016-01-29
AP2012006445A0 (en) 2012-08-31
PT3127542T (pt) 2018-11-26
CA3060290A1 (fr) 2011-08-04
JP2016145204A (ja) 2016-08-12
EA037601B1 (ru) 2021-04-20
LT3494972T (lt) 2024-03-12
EP2932970B1 (fr) 2018-03-21
JP6268386B2 (ja) 2018-01-31
CR20120423A (es) 2012-11-22
MX2012008774A (es) 2012-08-17
PL3494972T3 (pl) 2024-05-27
EP3127542B1 (fr) 2018-08-22
FR18C1043I1 (fr) 2018-11-30
ES2543066T3 (es) 2015-08-14
HRP20150770T1 (hr) 2015-08-28
NO2018036I1 (no) 2018-10-15
CN102791129A (zh) 2012-11-21
CY1121040T1 (el) 2019-12-11
MY188334A (en) 2021-11-30
JP2018127473A (ja) 2018-08-16
EP2531027A1 (fr) 2012-12-12
PH12016500195A1 (en) 2016-12-05
AP3551A (en) 2016-01-18
IL221007A0 (en) 2012-09-24
AU2011209788B2 (en) 2014-02-06
US20210401850A1 (en) 2021-12-30
EP3494972B1 (fr) 2023-12-13
MX367938B (es) 2019-09-12
EA201290583A1 (ru) 2013-04-30
CL2012002080A1 (es) 2012-11-30
SG10201707183TA (en) 2017-10-30
NO2932970T3 (fr) 2018-08-18
US20200230147A1 (en) 2020-07-23
BR112012018670A2 (pt) 2018-02-06
SI3127542T1 (sl) 2018-11-30
RS65183B1 (sr) 2024-03-29
IL267658A (en) 2019-08-29
FI3494972T3 (fi) 2024-03-01
EP3127542A1 (fr) 2017-02-08
US20150238496A1 (en) 2015-08-27
CA2967453C (fr) 2018-07-17
LT3127542T (lt) 2018-11-26
JP2021091705A (ja) 2021-06-17
PL2932970T3 (pl) 2018-08-31

Similar Documents

Publication Publication Date Title
MA34002B1 (fr) Thérapie antivirale
MA44674A (fr) Inhibiteurs de bromodomaine
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA42410A (fr) Oxystérols et leurs méthodes d'utilisation
MA39721A (fr) Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
MA31036B1 (fr) Inhibiteurs non nucleosidiques de la transcriptase inverse
MA34170B1 (fr) Inhibiteurs de transcriptase inverse non nucléosidiques
DE60318891D1 (de) Cyclopropylverbindungen als ccr5 antagonisten
MA31500B1 (fr) Composes chimiques
MA38182A1 (fr) Compositions pharmaceutiques a action prolongée pur une utilisation dans le traitement ou la prévention d'infections par le virus de l’immunodéficience humaine (vih)
MY186986A (en) Compositions and methods of use of phorbol esters
WO2016109217A3 (fr) Inhibiteurs de la btk
MA38349A1 (fr) Œstra-1,3,5(10),16-tétraéno-3-carboxamide pour inhiber la 17-bêta-hydroxystéroïde déshydrogénase (akr1c3)
MA48486B1 (fr) Polymères liant les protons pour administration orale
MA39447A1 (fr) (s)-pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
MA39448B1 (fr) (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical
MA31902B1 (fr) Oxazolidinones pour le traitement et/ou la prophylaxie de l'insuffisance cardiaque
MA40805A (fr) Compositions pharmaceutiques à action prolongée contre l'hépatite c
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA39446A1 (fr) Compositions pharmaceutiques pour traiter des maladies infecteuses
MA46625B1 (fr) Inhibiteurs de lsd1 et leurs utilisations médicales